With the advent of systemic ccRCC treatment modalities, including the application of tyrosine kinase inhibitors (TKIs), vascular endothelial growth factor receptors (VEGFRs), mammalian target rapamycin (mTOR) pathway inhibitors, and immune checkpoint inhibitors, has shown promising therapeutic efficacy [5]. This evidence concerns the gene MTOR and nonpapillary renal cell carcinoma.